Patents Assigned to BIONTECH US INC.
  • T cell manufacturing compositions and methods
    Patent number: 12258581
    Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: March 25, 2025
    Assignees: BioNTech US Inc., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhis
    Inventors: Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Burg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker
  • Neoantigens and uses thereof
    Patent number: 12246067
    Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: March 11, 2025
    Assignee: BioNTech US Inc.
    Inventor: Vikram Juneja
  • HLA-based methods and compositions and uses thereof
    Patent number: 11965892
    Abstract: Systems, compositions, and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 23, 2024
    Assignee: BioNTech US Inc.
    Inventors: Jennifer Grace Abelin, Rob Carl Oslund, Nir Hacohen, Dominik Barthelme, Michael Rooney
  • Neoantigens and uses thereof
    Patent number: 11793867
    Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: October 24, 2023
    Assignee: BIONTECH US INC.
    Inventor: Vikram Juneja
  • HLA-based methods and compositions and uses thereof
    Patent number: 11650211
    Abstract: Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: May 16, 2023
    Assignee: BioNTech US INC.
    Inventors: Jennifer Grace Abelin, Rob Carl Oslund, Nir Hacohen, Dominik Barthelme, Michael Rooney
  • Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
    Patent number: 11183272
    Abstract: Methods for preparing a personalized cancer vaccine and a method to train a machine-learning HLA-peptide presentation prediction model.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 23, 2021
    Assignee: BIONTECH US INC.
    Inventors: Michael Steven Rooney, Jennifer Grace Abelin, Dominik Barthelme, Robert Kamen
  • T cell manufacturing compositions and methods
    Patent number: 11162072
    Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: November 2, 2021
    Assignees: BIONTECH US INC., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhuis
    Inventors: Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Berg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker